Ash Stevens wins SOCMA Silver Awards

Company: Piramal Pharma Solutions

CEO Steve Munk also joins SOCMA board

Ash Stevens, a US-based contract pharmaceutical manufacturer and developer, received two Silver Awards for the successful continuation of its environmental, health, safety and security (EHS&S) programme sponsored by ChemStewards, an initiative of the Society of Chemical Manufacturers and Affiliates (SOCMA). The award, presented annually by SOCMA, recognised Ash Stevens’ Riverview, Michigan facility for implementing a scheme that successfully reduces the environmental footprint of companies that handle and manufacture chemicals, as well as ensuring compliance with all current environmental health and safety regulations.

‘This is the second consecutive year our plant in Riverview has been honoured by SOCMA,’ said Ash Stevens’ president and ceo Stephen Munk.

‘It is tremendously gratifying to have our commitment to the highest possible standards of environmental safety be honoured by an organisation whose primary purpose is to encourage such programmes.’

Munk has joined SOCMA’s Board of Governors. He was elected to the Board during the organisation’s 89th Annual Membership Meeting in New York.

‘As a long time SOCMA member, I look forward to assisting the Board in ensuring that the mission, policies and strategic direction of the association are aligned with membership needs,’ he said.

SOCMA’s Board of Governors provides strategic direction, maintains fiscal responsibility, and helps management develop business plans to deliver member value.

You may also like

Manufacturing

Piramal Pharma Solutions announces partnership with Botanix to support drug substance development

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra
Manufacturing

Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility

The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market
Manufacturing

Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services collaborate to support ADC development and manufacturing

Piramal and Ajinomoto Bio-Pharma Services have entered a collaborative arrangement aimed at enhancing their customers’ ADC development and manufacturing programs
Manufacturing

Piramal Pharma Solutions commemorates 20th anniversary at Morpeth Facility with procurement of Korsch X3

The Korsch X3 is a state-of-the-art tablet press, custom-built to fit the site’s needs. This positions Morpeth to support an increased demand for complex therapies
Manufacturing

Piramal Pharma Solutions’ Grangemouth facility successfully delivers 1500th ADC batch

With this achievement, Piramal strengthens its leadership position in delivering critical bioconjugate therapies to patients in need
Finance

Piramal Pharma Limited announces results for Q3 and 9M FY26

Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31st December 2025
Ingredients

Piramal Pharma Solutions introduces tablet-in-capsule capabilities

Enhancing dosing flexibility and patient-centric drug delivery
Subscribe now